CSI Market
Sign In | Register

Teva Pharmaceutical Industries Limited (TEVA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access TEVA Annual Cash Flow →
Quarterly cash flow trends provide additional context on Teva Pharmaceutical Industries Limited's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-207.00
Depreciation & amortization480.00
Amortization of Other Assets276.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Goodwill, Impairment Loss177.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-152.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation83.00
Income (Loss) from Equity Method Investments1.00
Financial Instruments and Foreign Currency Transaction0.00
Deferred Income Taxes Net And Uncertain Tax Positions-22.00
Gain From Revaluation Of Investments-
Venezuela Remeasurement Impact-
Research And Development Expense-
Increase Decrease In Certain Current Liabilities Excluding Debt-144.00
Impairment Of Investments-
Profit From Sale Of Long Lived Assets And Investment-8.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital780.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1,067.00
Discontinued operations0.00
Net Cash flow from Operating Activities371.00
Investing Activities
Capital Expenditures-273.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payment To Aquire Marketable Securities And Other Assets-
Cash Flows Between Transferor And Transferee Beneficial Interest-
Payment To Acquire Marketable Securities And Other Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Proceeds from Sale, Maturity and Collection of Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses46.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-3.00
Other Net-33.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-263.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-23.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock39.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net35.00
Other net-39.00
Proceeds From Senior Notes Net Of Issuance Costs-
Proceeds From Long Term Loans And Other Long Term Liabilities-
Proceeds From Senior Notes Net-
Payments Of Dividends Preferred Stock-
Payments Related To Tax Withholding For Shares And Dividend-
Repayment Of Convertible Debt-
Debt Conversion Converted Instrument Amount-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents3,556.00
Proceed From Minority Non Controlling Shareholders-
Dividends Paid To Non Controlling Interests-
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities12.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow98.00
Total Cash Flow99.00
4 historic quarters locked

Sign in to unlock the full Teva Pharmaceutical Industries Limited cash flow history.

Sign In Create Free Account

About Teva Pharmaceutical Industries Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 29, 2026
  • Source: d118828d10q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-323619

Figures are derived from filed reports and may be restated. Historical data is subject to revision.